Monoclonal antibody DLC-48: An effective reagent for use in the depletion of malignant lymphoma from human bone marrow

✍ Scribed by Jane N. Winter; Robert J. Marder; James A. Radosevich; Alan L. Epstein

• Publisher: John Wiley and Sons
• Year: 1987
• Tongue: French
• Weight: 891 KB
• Volume: 39
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910390603

✦ Synopsis

A combination of large-cell lymphoma cell lines was used as immunogen in the production of DLC-48, a mouse monoclonal antibody (MAb) to a B-cell-associated antigen. This reagent identifies a protein found on a majority of peripheral blood B-cells, B-cell derived tumor cell lines, and lymphoma biopsy specimens. In reactive lymph-node sections, DLC-48 stains both germinal center and mantle zone B-lymphocytes when the immunoperoxidase technique is used. DLC-48 is an IgM, and is highly cytotoxic in the presence of human serum complement. The conditions for complement-mediated cytotoxicity were first optimized by utilizing the chromium-release assay with 2 large-cell lymphoma cell lines, and were then applied to the treatment of the cell lines prior to cloning in agar. A single treatment with antibody and human serum eliminated 4 orders of magnitude of target cells. The cytolytic activity of this antibody was not inhibited by the presence of a 20-fold excess of normal human bone marrow. Treatment with antibody and autologous serum did not affect the growth of human hematopoietic progenitor cells (CFU-GEMM and CFU-GM). These results suggest that DLC-48, either alone or in combination with other MAb reagents, should be effective in eliminating malignant cells of B-lineage from human bone marrow for purposes of autologous bone-marrow transplantation.